oalib
Search Results: 1 - 10 of 100 matches for " "
All listed articles are free for downloading (OA Articles)
Page 1 /100
Display every page Item
Desarrollo de esmaltes nanoestructurados multifuncionales  [cached]
Jaquotot, P.,Campillo, A.,Reinosa, J. J.,Romero, J. J.
Boletín de la Sociedad Espa?ola de Cerámica y Vidrio , 2009,
Abstract: The development of new glazes with innovative characteristics for the tile industry was afforded by using disperse nanoparticles on host sepiolite particles. Sepiolite clay has fibrillar morphology with a diameter < 50 nm and with a composition compatible with the glaze. The host particles were conditioned to support and to protect different disperse nanoparticles having metallic or oxidic nature. The developed glazes possess a nanostructure which is responsible for different properties. Different functionalities could be combined in a single glaze as a multifunctional glaze: metallic aspect, hydrophobic response, bactericide and fungicide properties, and self cleaning characteristics. The efficiency of the supported nanoparticles allows the use of the nanoparticles technology to obtain multifunctional glazes and powered the innovations into the tile product with added value. El desarrollo de nuevos esmaltes con características innovadoras para la industria de pavimentos y revestimientos cerámicos se ha realizado mediante la dispersión de nanopartículas sobre partículas matriz basadas en fibras de sepiolita de diámetro nanométrico, < 50 nm. La sepiolita es una arcilla fibrilar de composición compatible con el esmalte. Los aspectos más relevantes de la investigación realizada han permitido acondicionar las partículas matrices para soportar y proteger diferentes tipos de nanopartículas dispersas de naturaleza metálica u oxídica. Los esmaltes desarrollados tienen la cualidad de encontrarse nanoestructurados y ser multifuncionales, ya que pueden combinarse en un solo esmalte diferentes propiedades como la de tener aspecto metalizado, propiedades hidrofóbicas, bactericidas, fungicidas y de autolimpieza. El concepto de nanopartículas soportadas utiliza de forma eficiente los procesos actuales de tecnología de nanopartículas para obtener multifuncionalidades en los esmaltes, ofreciendo producto cerámico innovador y de mayor valor a adido.
The Rule Responder eScience Infrastructure  [PDF]
Adrian Paschke,Zhili Zhao
Computer Science , 2010,
Abstract: To a large degree information and services for chemical e-Science have become accessible - anytime, anywhere - but not necessarily useful. The Rule Responder eScience middleware is about providing information consumers with rule-based agents to transform existing information into relevant information of practical consequences, hence providing control to the end-users to express in a declarative rule-based way how to turn existing information into personally relevant information and how to react or make automated decisions on top of it.
Love Styles and Cardiovascular Responder Types
Kenta Matsumura,Takehiro Yamakoshi,Peter Rolfe
International Journal of Psychological Studies , 2011, DOI: 10.5539/ijps.v3n2p21
Abstract: We examined the relationship between cardiovascular responder types and love styles. Cardiovascular responder types were measured as reactivity to a social speech task. Measures included heart rate (HR), systolic and diastolic blood pressure (SBP and DBP, respectively), pre-ejection period (PEP), and baroreceptor sensitivity (BRS). Love styles were measured using the 2nd version of Lee’s Type Scale; a questionnaire developed based on Lee’s color theory. Analyses revealed that Eros (physically attracted love) score was related to HR, SBP, and BRS reactivity, and that Mania (obsessive and jealous love) score was related to HR and BRS reactivity. These results suggest that passionate love style, including Eros and Mania, is associated with cardiovascular responder types.
A Usaid, a guerra fria, o Regime Militar e a implanta o das Escolas Polivalentes no Brasil
José Alfredo Araújo
Ciência & Desenvolvimento , 2010,
Abstract: Resultado dos acordos MEC/USAID, as Escolas Polivalentes foram ent o implantadas e colocadas em prática no Brasil do Regime Militar. Portanto, rela es políticas no contexto político internacional no qual o Brasil estava inserido – os efeitos da Guerra Fria na América Latina. Sendo assim, o programa de ajuda da Alian a para o Progresso, através da USAID (Agência Norte-Americana para o Desenvolvimento Internacional), e o MEC (Ministério da Educa o e Cultura), só foi possível ser intensificado após o Golpe Militar ocorrido em 1964, pois havia, a partir daquele momento, toda uma estrutura, no Estado, pronta para que o convênio USAID/MEC fosse colocado em prática por meio do aparelho educacional. Neste momento ocorre a transforma o da EPEM (Equipe de Planejamento do Ensino Médio) no PREMEM (Programa de Expans o e Melhoria do Ensino Médio), resultando todas estas rela es e transforma es na implanta o das escolas Polivalentes no Brasil.
First Responder ECHO: Developing an Innovative Telementoring Program  [PDF]
Neil Katzman, Jessica Medrano, Robin Swift, Paige Menking
Creative Education (CE) , 2019, DOI: 10.4236/ce.2019.109144
Abstract: First Responders across the globe suffer from increased rates of?post-traumatic stress disorder (PTSD), depression, and compassion fatigue. Because their work environment places them on the front lines of crisis situations nearly every day, first responders experience a significant amount of trauma, which can lead to PTSD and other psychological symptoms. Project ECHO, a successful telementoring program, whose mission is to educate clinicians and other health care providers in rural and underserved communities, will be piloting a First Responder ECHO beginning September 2019. The primary goal of the First Responder ECHO is to improve the confidence and knowledge of First Responders in New Mexico. This First Responder ECHO will include an evaluation component. If the program is successful, the goal will be to expand to other regions of the United States.
Gibt es Non-Responder auf rehabilitatives Training nach Herzinfarkt?  [PDF]
Schmid P,Bronnenmayer J,Gradauer L,Helmreich G
Journal für Kardiologie , 2004,
Abstract: Bei 460 m nnlichen und 110 weiblichen Postinfarktpatienten wurde im Rahmen eines 3w chigen station ren Wiederholungsaufenthaltes die Frage nach dem Ausma der Verbesserung der maximalen Leistungsf higkeit durch Bewegungstherapie und das Nichtansprechen (= Non-Responder) auf die selbe in Abh ngigkeit vom Lebensalter untersucht. Als Zeichen eines erfolgreich durchgeführten, herzfrequenzgesteuerten Ausdauertrainings bestehend aus Terraintraining, Fahrradergometertraining und Gymnastik fand sich im Gesamtkollektiv (n = 570) eine Senkung von Herzfrequenz, Blutdruck und Doppelprodukt (= RRsys × HF) in Ruhe sowie eine Erh hung der relativen maximalen Leistungsf higkeit (= Wmax/kg) bei der Entlassungsergometrie gegenüber der Eingangsergometrie um 15,4 % bei M nnern und um 13,2 % bei Frauen; bei den über 70j hrigen betrugen die Steigerungsraten 17,8 % (M nner) und 12,5 % (Frauen). Bei 25 Patienten kam es zu keiner Leistungssteigerung bzw. zu einer Leistungsverschlechterung, für die in 19 F llen eine eindeutige Erkl rung gefunden werden konnte. Bei den restlichen 6 Patienten war für die fehlende Leistungssteigerung in zwei F llen m glicherweise ein übertrainingssyndrom verantwortlich, die restlichen 4 Patienten sind entweder echte Non-Responder oder sie haben sich aufgrund fehlender Motivation bei der Entlassungsergometrie nicht voll verausgabt. Zusammenfassend ist festzuhalten, da es in der vorliegenden Form der Bewegungstherapie von Postinfarktpatienten nur in verschwindendem Ausma Non-Responder gibt und diese Trainingsform daher weiterhin als fixer Bestandteil einer erfolgreichen Herz-Kreislauf-Rehabilitation anzusehen ist.
METHYLPREDNISOLONE PULSE THERAPY IN MANAGEMENT OF NON RESPONDER NEPHROTIC SYNDROME
A. Madani,S.T. Esfahani N. Ataei
Acta Medica Iranica , 1999,
Abstract: Some patients with the diagnosis of childhood nephrotic syndrome are unresponsive to conventional treatment regimens. Recent studies of more aggressive therapies have provided strong evidence of the benefit of high dose methylprednisolonc (MP) protocol with alternate - day prednisone alone or with alternate - day prednisone plus an alkylating agent (I) in these patients."nFrom May 1996 to May 1997 we have treated 14 patients with non-responder nephrotic syndrome with mcthyprcdnisolone protocol. Eight patients had histologic diagnosis of focal segmental glomerulosclerosis, 3 diffuse mesangial proliferation and 3 has minimal change disease. C'ylosporin was added in two patients to methylprcdnisotonc at the beginning of the second course of therapy. Tfie patients were observed for an average of 8 months (range 4-12 months). In the last follow up there were no patients in remission and all remained nephrotic. Seven patients had persistent massive proteinuria with normal creatinine clearance (CrCI). Two had decreased CrCl. Five progressed to end-stage renal disease. Tlicsc observations suggest that "Puke" methy{prednisolone is not effective in patients with non respondcr nephrotic syndrome.
Development of an IgG4-RD Responder Index  [PDF]
Mollie N. Carruthers,John H. Stone,Vikram Deshpande,Arezou Khosroshahi
International Journal of Rheumatology , 2012, DOI: 10.1155/2012/259408
Abstract: IgG4-related disease (IgG4-RD) is a multiorgan inflammatory disease in which diverse organ manifestations are linked by common histopathological and immunohistochemical features. Prospective studies of IgG4-RD patients are required to clarify the natural history, long-term prognosis, and treatment approaches in this recently recognized condition. Patients with IgG4-RD have different organ manifestations and are followed by multiple specialties. Divergent approaches to the assessment of patients can complicate the interpretation of studies, emphasizing the critical need for validated outcome measures, particularly assessments of disease activity and response to treatment. We developed a prototype IgG4-RD Responder Index (IgG4-RD RI) based on the approach used in the development of the Birmingham Vasculitis Activity Score for Wegener’s granulomatosis (BVAS/WG). The IgG4-RD RI was refined by members of the International IgG4-RD Symposium Organizing Committee in a paper case exercise. The revised instrument was applied retrospectively to fifteen IgG4-RD patients at our institution. Those scores were compared to physician’s global assessment scale for the same visits. This paper describes the philosophy and goals of the IgG4-RD RI, the steps in the development of this instrument to date, and future plans for validation of this instrument as an outcome measure. 1. Introduction Measurement of disease activity is critical for longitudinal assessments in both observational studies and clinical trials. In the field of rheumatology, more than 250 assessment tools have been developed and validated to evaluate pathology, symptoms, function, and health status of patients with rheumatic diseases [1]. Such instruments should be compatible with regulatory requirements of the Food and Drug Administration (FDA) and generally require prospective studies for completion of the validation process [2]. IgG4-related disease (IgG4-RD) is an increasingly recognized immune-mediated disease that is characterized by a lymphoplasmacytic infiltrate enriched with IgG4-positive plasma cells and a distinctive storiform fibrosis of affected organs [3]. Commonly involved organs include the pancreas, biliary tree, orbits, salivary glands, and retroperitoneum, among many others. Organ involvement usually occurs in a metachronous but overlapping fashion. The serum IgG4 level is often but not always elevated [4]. Because of the novelty of IgG4-RD, little effort to date has been devoted to the development of outcome measures for this newly recognized condition. A disease responder index is a
Responder analyses and the assessment of a clinically relevant treatment effect
Steven M Snapinn, Qi Jiang
Trials , 2007, DOI: 10.1186/1745-6215-8-31
Abstract: A clinical endpoint used to determine the efficacy of an experimental treatment can be measured on a variety of scales, including a continuous scale, an ordinal scale, or a binary scale. One important goal common to many clinical trials is determining whether or not the effect of the experimental treatment is significantly better than that of the control treatment, and this goal can be achieved using measurements based on any of these scales. However, it is not only important to assess statistical significance, but also to assess the clinical relevance of the effect, and the assessment of clinical relevance has received much less attention in the statistical literature. The purpose of this paper is to discuss some of the issues associated with the assessment of clinical relevance, focusing in particular on an approach known as the "responder analysis" that involves dichotomizing a continuous or ordinal variable into a binary variable.One potential approach to assess clinical relevance is to define a clinically relevant effect, and test the null hypothesis that the true effect is of this size or less versus the hypothesis that the true effect is greater than the clinically relevant effect. For example, suppose that the clinical endpoint is a continuous variable, X, such that larger values represent better efficacy, and that there is interest in the mean difference in this endpoint, μ, between the experimental treatment and the control. Note that X could represent a measurement taken at the conclusion of the trial or a change in that measurement from its baseline value. The typical null hypothesis (assuming one-sided testing) is that of no difference, or μ ≤ 0, versus the alternative hypothesis μ > 0. However, if one were to define a minimum clinically important difference, μ0, then one could test the null hypothesis μ ≤ μ0 versus the alternative hypothesis μ > μ0. This hypothesis is sometimes referred to as "super superiority," and a statistically significant result
Pregabalin in fibromyalgia - responder analysis from individual patient data
Sebastian Straube, Sheena Derry, R Andrew Moore, Jocelyn Paine, Henry J McQuay
BMC Musculoskeletal Disorders , 2010, DOI: 10.1186/1471-2474-11-150
Abstract: We obtained individual patient data from four randomised double blind trials of pregabalin in fibromyalgia lasting eight to 14 weeks. We calculated response for all efficacy outcomes using any improvement (≥ 0%), minimal improvement (≥ 15%), moderate improvement (≥ 30%), substantial improvement (≥ 50%), and extensive improvement (≥ 70%), with numbers needed to treat (NNT) for pregabalin 300 mg, 450 mg, and 600 mg daily compared with placebo.Information from 2,757 patients was available. Pain intensity and sleep interference showed reductions with increasing level of response, a significant difference between pregabalin and placebo, and a trend towards lower (better) NNTs at higher doses. Maximum response rates occurred at 4-6 weeks for higher levels of response, and were constant thereafter. NNTs (with 95% confidence intervals) for ≥ 50% improvement in pain intensity compared with placebo after 12 weeks were 22 (11 to 870) for pregabalin 300 mg, 16 (9.3 to 59) for pregabalin 450 mg, and 13 (8.1 to 31) for pregabalin 600 mg daily. NNTs for ≥ 50% improvement in sleep interference compared with placebo after 12 weeks were 13 (8.2 to 30) for pregabalin 300 mg, 8.4 (6.0 to 14) for pregabalin 450 mg, and 8.4 (6.1 to 14) for pregabalin 600 mg. Other outcomes had fewer respondents at higher response levels, but generally did not discriminate between pregabalin and placebo, or show any dose response. Shorter duration and use of 'any improvement' over-estimated treatment effect compared with longer duration and higher levels of response.Responder analysis is useful in fibromyalgia, particularly for pain and sleep outcomes. Some fibromyalgia patients treated with pregabalin experience a moderate or substantial pain response that is consistent over time. Short trials using 'any improvement' as an outcome overestimate treatment effects.Fibromyalgia is surrounded by controversy regarding its aetiology and its status as a valid disease entity. Genetic and neurobiological evidence
Page 1 /100
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.